Tesaro gets $5.1 billion takeover bid

3 December 2018

There has been much speculation in recent weeks that US drugmaker and PARP inhibitor specialist Tesaro (Nasdaq: TSRO) had put itself up for sale that has already sent the firm’s shares higher, but today they leapt more than 59% to $73.95 in pre-market trading after it was revealed that it has reached agreement to be taken over.

UK pharma major GlaxoSmithKline (LSE: GSK) today announced that it has entered into a definitive agreement to acquire Tesaro for an aggregate cash consideration of around $5.1 billion (£4.0 billion). The proposed transaction will significantly strengthen GSK’s pharmaceutical business, accelerating the build of GSK’s pipeline and commercial capability in oncology. Tesaro shares were trading for $75 at the beginning of the year, so this deal only brings the stock to break even. GSK’s shares fell 6.08% to £15.22 by early afternoon.

The acquisition price of $75 per share in cash represents a 110% premium to Tesaro’s 30 day Volume Weighted Average Price of $35.67 for a total of about $5.1 billion including the assumption of Tesaro’s net debt.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK